Zymeworks Q3 2025: Narrower-than-expected loss and strong cash position, though revenue missed estimates. Clinical pipeline advances with promising data.
Civitas Resources (CIVI) reported strong Q3 2025 earnings, beating EPS estimates by 44%. Revenue was slightly below forecasts. The company also announced a pending merger with SM Energy.
AerSale's Q3 2025 earnings missed estimates, causing a stock drop. Despite a revenue decline, the company saw growth in leasing and USM sales as it shifts its strategy.
Heritage Global (HGBL) Q3 2025 results missed revenue and earnings estimates, causing a stock drop. The company cited economic uncertainty impacting transaction sizes.
American Healthcare REIT (AHR) smashed Q3 2025 earnings estimates, reporting EPS of $0.44 vs. $0.16 forecast. The strong results prompted management to raise its full-year 2025 guidance.
Monster Beverage beats Q3 estimates with strong revenue growth of 16.8% and a significant jump in earnings per share, sparking a positive market reaction.
Universal Electronics (UEIC) beat Q3 2025 earnings estimates by 57%, driving shares up despite a revenue miss. The company eyes its first full-year profit since 2022.
Sensus Healthcare (SRTS) beat Q3 2025 earnings estimates despite a revenue dip. The company highlighted a key regulatory win with new CPT codes for its skin cancer treatment technology.
Take-Two Interactive beat Q2 earnings and revenue estimates but its stock fell after announcing a six-month delay for Grand Theft Auto VI to November 2026.
Natera (NTRA) Q3 2025 results beat revenue forecasts with $592.2M, driven by strong oncology test growth. The company raised its full-year 2025 guidance.
MidCap Financial (MFIC) reported Q3 2025 earnings, with revenue slightly missing estimates while EPS was in line. The company also announced a new dividend and portfolio de-risking.
Relay Therapeutics reports Q3 2025 results, missing revenue estimates. The biotech firm maintains a strong cash position to fund its clinical trials for lead drug RLY-2608 into 2029.
The best AI plays aren’t necessarily tech start-ups or chipmakers. They’re established, cash-generating businesses that use AI to strengthen their already winning models.
Tandem Diabetes Care (TNDM) beat Q3 2025 earnings and revenue estimates, driving a 16% stock surge. The company reported strong sales growth and improved margins.
Assured Guaranty (AGO) reported strong Q3 2025 earnings, beating revenue and EPS estimates. The Insurance segment drove growth with record U.S. public finance production.
Nu Skin (NUS) reported mixed Q3 results, beating earnings estimates but missing on revenue. The company faces sales declines while improving profitability.
News Corp (NWSA) Q1 FY2026 earnings beat EPS estimates with $0.22, driven by strong Dow Jones and Digital Real Estate results, despite a muted market reaction.
Northern Oil and Gas (NOG) Q3 2025 earnings beat EPS estimates despite a revenue miss. The stock rose as strong profitability and cost control offset lower sales.
The Trade Desk (TTD) beat Q3 revenue estimates with $739M and issued strong Q4 guidance. The stock's muted reaction highlights high market expectations.
Financial guaranty insurer Assured Guaranty (NYSE:AGO) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales fell by 23% year on year to $207 million. Its non-GAAP profit of $2.57 per share was 67.2% above analysts’ consensus estimates.
Nerdy Inc. (NRDY) posted mixed Q3 2025 results, missing revenue estimates but beating on profitability. The stock rose as cost cuts and a narrower loss impressed investors.
Lineage Cell Therapeutics reports Q3 2025 results with a revenue beat but a wider net loss. The company advances its cell therapy pipeline and has cash into 2027.
